Erectile Dysfunction Labs and Next Steps: A Clinical Guide

Why Erectile Dysfunction Happens

ED results from disrupted coordination between vascular, neurological, hormonal, and psychological systems. Roughly 80% of cases have an organic basis, with arterial insufficiency being the single most common contributor [1].

The physiology is straightforward. Erection depends on nitric oxide release from cavernous nerve terminals, which triggers smooth muscle relaxation in the corpora cavernosa and allows arterial inflow. Anything that damages endothelial function, reduces nitric oxide bioavailability, or disrupts nerve signaling can impair this chain. Diabetes is the most potent single risk factor. The Massachusetts Male Aging Study (MMAS) found that men with treated diabetes had a 28% age-adjusted prevalence of complete ED, compared with 9.6% in the general cohort [2]. Hypertension, dyslipidemia, obesity, and smoking each contribute independent risk through endothelial injury and atherosclerotic narrowing of the penile arteries [3].

Hormonal causes account for a smaller but clinically significant subset. The Endocrine Society's 2018 guideline notes that testosterone deficiency (total testosterone <300 ng/dL on two morning samples) affects 20 to 40% of men presenting with ED, though low testosterone alone is rarely the sole cause [4]. Psychogenic ED, driven by performance anxiety, depression, or relationship conflict, predominates in men under 40. A mixed picture (organic plus psychogenic) is common across all age groups.

Medications deserve scrutiny. SSRIs, beta-blockers, thiazide diuretics, 5-alpha reductase inhibitors, and opioids all carry ED as a recognized side effect. A careful medication reconciliation is one of the highest-yield steps in any ED evaluation.

The Standard Lab Workup

A morning fasting blood draw is the foundation of ED diagnostics. The American Urological Association (AUA) and the Sexual Medicine Society of North America (SMSNA) jointly recommend a focused panel rather than an exhaustive screen [5].

Core labs:

• Fasting glucose and/or HbA1c. Undiagnosed diabetes or prediabetes is found in up to 15% of men presenting with new ED [6]. An HbA1c of 6.5% or higher confirms diabetes; 5.7 to 6.4% signals prediabetes.
• Lipid panel. Total cholesterol, LDL, HDL, and triglycerides. Dyslipidemia accelerates penile arterial disease.
• Total testosterone. Drawn before 10 a.m., when diurnal levels peak. If the first result falls below 300 ng/dL, a confirmatory repeat with free testosterone and sex hormone-binding globulin (SHBG) is indicated.
• Thyroid-stimulating hormone (TSH). Both hypothyroidism and hyperthyroidism impair erectile function and libido. Correction of thyroid abnormalities alone resolves ED in a subset of patients [7].

Second-tier labs (ordered when clinical suspicion warrants):

• Prolactin, if testosterone is low or the patient reports decreased libido without clear explanation. Hyperprolactinemia suppresses GnRH pulsatility and can indicate a pituitary adenoma.
• Luteinizing hormone (LH) and follicle-stimulating hormone (FSH), to distinguish primary from secondary hypogonadism.
• Comprehensive metabolic panel, to screen for renal or hepatic dysfunction.
• PSA, before initiating testosterone therapy in men over 40, per Endocrine Society guidance [4].

Dr. Arthur Burnett, Professor of Urology at Johns Hopkins and a lead author of the AUA ED guideline, has stated: "The lab evaluation for ED is not about running every test available. It is about identifying the two or three modifiable risk factors that, once treated, give the patient the best chance of recovery" [5].

ED as a Cardiovascular Warning Sign

Treat ED as a vascular red flag. This is not optional.

The Princeton III Consensus Panel classifies ED as an independent risk factor for future cardiovascular events [8]. A meta-analysis published in the Journal of the American College of Cardiology (12 prospective studies, N=36,744) found that men with ED had a 44% increased risk of total cardiovascular events (RR 1.44, 95% CI 1.27 to 1.63), a 62% increased risk of myocardial infarction, and a 39% increased risk of cerebrovascular events compared with men without ED [9]. The shared pathophysiology is endothelial dysfunction. Because the penile arteries (1 to 2 mm diameter) are smaller than coronary arteries (3 to 4 mm), they occlude earlier. ED symptoms typically precede a cardiac event by a mean of 2 to 3 years [9].

The practical takeaway: every man diagnosed with ED and no known cardiac history should receive cardiovascular risk stratification. That means, at minimum, a fasting lipid panel, blood pressure measurement, fasting glucose, and a calculated 10-year ASCVD risk score. The Princeton III guidelines recommend that men with ED and intermediate cardiac risk undergo exercise stress testing before starting sexual activity or PDE5 inhibitor therapy [8].

Dr. Graham Jackson, a cardiologist and co-author of the Princeton Consensus, wrote: "A man with erectile dysfunction and no cardiac symptoms is a cardiac patient until proven otherwise" [8]. That principle should guide every clinician's approach to the ED workup.

First-Line Treatment: PDE5 Inhibitors

Phosphodiesterase type 5 inhibitors remain the first-line pharmacologic therapy for ED regardless of etiology. Four agents are FDA-approved: sildenafil (Viagra), tadalafil (Cialis), vardenafil (Levitra), and avanafil (Stendra) [10].

These drugs work by inhibiting PDE5, the enzyme responsible for degrading cyclic GMP in cavernous smooth muscle. The result is prolonged smooth muscle relaxation and enhanced arterial inflow during sexual stimulation. They do not cause erections without arousal.

Efficacy data from large randomized trials:

• Sildenafil: In the original key trial (N=532), 69% of all attempts at intercourse were successful on sildenafil 100 mg versus 22% on placebo [10].
• Tadalafil: The LVHJ study (N=348) demonstrated that tadalafil 20 mg improved the International Index of Erectile Function (IIEF) erectile function domain score by a mean of 7.9 points from baseline, compared with 1.4 points for placebo [11].
• Avanafil: A phase III trial (N=646) showed that 200 mg avanafil taken 30 minutes before intercourse produced successful vaginal penetration in 64% of attempts versus 28% for placebo [12].

Tadalafil offers the option of daily low-dose (2.5 mg or 5 mg) therapy, which provides continuous drug levels and eliminates the need to time doses before sexual activity. Daily tadalafil also carries FDA approval for concurrent benign prostatic hyperplasia symptoms.

When PDE5 inhibitors fail. Roughly 30 to 35% of men do not respond adequately. Before labeling a patient as a non-responder, verify that the drug was taken correctly (on an empty stomach for sildenafil and vardenafil, adequate time before sexual activity, with sexual stimulation present) and that at least six attempts were made at the maximum tolerated dose. Optimization of testosterone levels to above 300 ng/dL may rescue PDE5 inhibitor response in hypogonadal men [4].

Testosterone Therapy: When It Applies

Testosterone replacement therapy (TRT) is indicated for men with confirmed hypogonadism (total testosterone <300 ng/dL on two separate morning draws) plus symptoms including ED, decreased libido, fatigue, or reduced lean mass [4].

The Testosterone Trials (TTrials), a coordinated set of seven placebo-controlled studies enrolling 790 men aged 65 and older with testosterone levels <275 ng/dL, found that testosterone gel for one year improved sexual desire (measured by the Psychosexual Daily Questionnaire) by a mean of 0.62 points versus placebo and increased sexual activity frequency [13]. The erectile function benefit was modest when testosterone was used alone but more pronounced when combined with PDE5 inhibitors.

The TRAVERSE trial (N=5,246), published in the New England Journal of Medicine in 2023, provided long-awaited cardiovascular safety data: testosterone replacement in men aged 45 to 80 with hypogonadism and established or high risk for cardiovascular disease did not increase the incidence of major adverse cardiovascular events (MACE) compared with placebo (HR 0.96, 95% CI 0.78 to 1.17) over a mean follow-up of 33 months [14]. This result shifted clinical practice by reducing the hesitancy around TRT in men with cardiac risk factors.

TRT formulations include topical gels (testosterone 1% or 1.62%), intramuscular injections (testosterone cypionate 100 to 200 mg every 1 to 2 weeks), subcutaneous pellets, and nasal gel. Selection depends on patient preference, insurance coverage, and the need for fertility preservation (exogenous testosterone suppresses spermatogenesis).

Lifestyle Modifications That Move the Needle

Lifestyle changes are not a consolation prize. They produce measurable improvements in erectile function, sometimes rivaling medication.

A randomized controlled trial published in JAMA (N=110 obese men with ED, no diabetes) found that two years of intensive lifestyle intervention (caloric restriction plus 195 minutes per week of moderate exercise) improved IIEF scores by 3.1 points more than the control group, and one third of participants in the intervention arm regained normal erectile function without any pharmacotherapy [15].

The specific interventions with the strongest evidence:

• Weight loss. A 5 to 10% reduction in body weight improves endothelial function, reduces inflammatory markers, and raises testosterone levels in obese men [15].
• Exercise. A 2018 meta-analysis in the British Journal of Sports Medicine (10 RCTs, N=543) found that aerobic exercise significantly improved IIEF-EF scores (mean difference 3.85 points, 95% CI 2.32 to 5.37) [16]. Resistance training produced additive benefits.
• Smoking cessation. Tobacco use doubles the risk of moderate-to-complete ED. Cessation improves endothelial function within weeks [3].
• Alcohol moderation. Heavy alcohol consumption (>21 drinks per week) is associated with ED through hepatic estrogen metabolism disruption and direct gonadal toxicity.
• Sleep optimization. Obstructive sleep apnea is independently associated with ED. CPAP therapy for 3 months improved erectile function in a small controlled trial (N=43) [17].

Mediterranean dietary patterns, rich in vegetables, whole grains, olive oil, and fish, have been linked to lower ED prevalence in observational cohorts. A prospective analysis from the Health Professionals Follow-Up Study (N=21,469) found that men with the highest adherence to a Mediterranean diet had a 22% lower risk of incident ED over 10 years [18].

Second-Line and Advanced Therapies

When PDE5 inhibitors and lifestyle changes are insufficient, several second-line options exist.

Intracavernosal injection therapy. Alprostadil (prostaglandin E1), alone or in combination with papaverine and phentolamine (trimix), is injected directly into the corpus cavernosum. Efficacy rates exceed 85% even in populations resistant to oral therapy, including post-prostatectomy patients [19]. The learning curve for self-injection is real but manageable with clinic-based training. The primary side effect is priapism (incidence roughly 1 to 3%), which requires patient education about when to seek emergency care.

Vacuum erection devices (VEDs). These create negative pressure around the penis, drawing blood into the corpora, followed by placement of a constriction ring at the base. Satisfaction rates range from 50 to 80% in published series. VEDs are particularly useful as rehabilitation tools after radical prostatectomy [5].

Penile prosthesis implantation. For men who fail or decline all other therapies, an inflatable penile prosthesis offers the highest satisfaction rates of any ED treatment (92 to 98% patient satisfaction, 96% partner satisfaction in a 15-year follow-up series) [20]. Modern three-piece inflatable devices consist of paired intracorporal cylinders, a scrotal pump, and an abdominal reservoir. The procedure carries infection risk of approximately 1 to 3% with antibiotic-coated devices.

Low-intensity extracorporeal shockwave therapy (Li-ESWT). A 2019 meta-analysis (7 RCTs, N=602) showed significant improvement in IIEF-EF scores (mean difference 2.00, 95% CI 0.99 to 3.00) compared with sham, with the strongest effect in men with vasculogenic ED [21]. Long-term durability data beyond 12 months remain limited.

When to See a Specialist

Primary care physicians can manage most ED cases through the initial workup and PDE5 inhibitor prescribing. Referral to a urologist or sexual medicine specialist is appropriate in specific scenarios.

Refer when: PDE5 inhibitors fail after proper optimization across at least two agents; the patient has Peyronie's disease with penile curvature; the workup reveals an endocrine abnormality requiring further evaluation (such as a prolactinoma); the patient is a candidate for intracavernosal injections, shockwave therapy, or surgical implantation; or the patient has a history of pelvic surgery or radiation.

Referral to a mental health professional (psychologist or sex therapist experienced in male sexual dysfunction) is indicated when psychogenic factors predominate, when relationship distress is a major contributor, or when the patient has comorbid depression or anxiety that may be maintaining the sexual dysfunction. Combination therapy (medication plus psychotherapy) outperforms either approach alone in mixed-etiology ED [5].

Men under 40 with no identifiable vascular risk factors deserve particular attention. Penile Doppler ultrasound can distinguish arteriogenic from venogenic ED in this population and may reveal congenital vascular variants or traumatic arterial injury amenable to surgical repair.

Schedule labs within two weeks of recognizing persistent erectile difficulty, defined as inability to achieve or maintain an erection sufficient for satisfactory intercourse on at least 50% of attempts over a three-month period. Earlier evaluation is warranted if symptoms appear suddenly, are accompanied by pain, or follow initiation of a new medication.